Home / Data / Women's Health Trial Tracker Women's Health Trial Tracker Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.
Records 5,000
Last changed 08/26/2026
Update schedule 55 1 * * * UTC
Coverage 05/26/2000–08/25/2026 Record Record Date Vuga Group Change Status Recency Days Public Significance Score Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer 09/13/2022 INTERVENTIONAL unchanged 1,443.85 0 Platelet Rich Plasma for Insufficient Endometrium 09/13/2022 INTERVENTIONAL unchanged 1,443.85 0 Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers 09/14/2022 INTERVENTIONAL unchanged 1,442.85 0 ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer 09/15/2022 INTERVENTIONAL unchanged 1,441.85 0 Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes 09/16/2022 INTERVENTIONAL unchanged 1,440.85 0 ED90 of Epidural Bupivacaine With Lidocaine for the Initiation of Labor Analgesia 09/16/2022 INTERVENTIONAL unchanged 1,440.85 0 Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women 09/21/2022 INTERVENTIONAL unchanged 1,435.85 0 A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma 09/21/2022 INTERVENTIONAL unchanged 1,435.85 0 Reduced Opioid Prescription After Laparoscopic Hysterectomy 09/21/2022 INTERVENTIONAL unchanged 1,435.85 0 Structured Contraceptive Counseling During Pregnancy 09/22/2022 INTERVENTIONAL unchanged 1,434.85 0 The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer 09/22/2022 INTERVENTIONAL unchanged 1,434.85 0 Safest Choice of Antihypertensive Regimen for Postpartum Hypertension 09/22/2022 INTERVENTIONAL unchanged 1,434.85 0 Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi 09/22/2022 INTERVENTIONAL unchanged 1,434.85 0 IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer 09/22/2022 INTERVENTIONAL unchanged 1,434.85 0 Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women 09/23/2022 INTERVENTIONAL unchanged 1,433.85 0 The Effect of ASTARTE™ on Recurrent Urinary Tract Infection 09/23/2022 INTERVENTIONAL unchanged 1,433.85 0 Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health 09/23/2022 OBSERVATIONAL unchanged 1,433.85 0 Effect of Standardization of Urine Collection Using PEEZY Device as Compared to Clean Peezy for DAB 09/26/2022 INTERVENTIONAL unchanged 1,430.85 0 Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial 09/26/2022 INTERVENTIONAL unchanged 1,430.85 0 Optimizing Screening for Cervical Cancer Among Women Living With HIV in the Dominican Republic 09/27/2022 INTERVENTIONAL unchanged 1,429.85 0 Cohort of Patients Presenting Unexplained Recurrent Miscarriages and Identification of Early Miscarriage Recidivism Factors 09/27/2022 OBSERVATIONAL unchanged 1,429.85 0 Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer 09/28/2022 INTERVENTIONAL unchanged 1,428.85 0 Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer 09/28/2022 INTERVENTIONAL unchanged 1,428.85 0 Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted 09/29/2022 INTERVENTIONAL unchanged 1,427.85 0 Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma 09/29/2022 INTERVENTIONAL unchanged 1,427.85 0 Can the Use of a Next Generation Partograph Improve Neonatal Outcomes? (PICRINO) 09/29/2022 INTERVENTIONAL unchanged 1,427.85 0 Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries) 09/30/2022 OBSERVATIONAL unchanged 1,426.85 0 Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women At Higher Risk 10/03/2022 INTERVENTIONAL unchanged 1,423.85 0 Women Hypertensive and Young-Renal Denervation 10/03/2022 INTERVENTIONAL unchanged 1,423.85 0 Exploring Virtual Reality Adventure Training Exergaming 10/03/2022 INTERVENTIONAL unchanged 1,423.85 0 Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV 10/04/2022 OBSERVATIONAL unchanged 1,422.85 0 Testing Multi-Level Remote Physical Activity Interventions in a National Sample of Older Women: The WHISH EnCore Trial 10/04/2022 INTERVENTIONAL unchanged 1,422.85 0 Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires 10/05/2022 OBSERVATIONAL unchanged 1,421.85 0 Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study 10/05/2022 INTERVENTIONAL unchanged 1,421.85 0 Evaluation of Young United Parents 10/06/2022 INTERVENTIONAL unchanged 1,420.85 0 An Open Labeled RCT on the Effect of Additional hCG Injection for LPS on Pregnancy Outcomes in IHH Patients 10/06/2022 INTERVENTIONAL unchanged 1,420.85 0 Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes 10/06/2022 INTERVENTIONAL unchanged 1,420.85 0 A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 10/06/2022 INTERVENTIONAL unchanged 1,420.85 0 1/2- Bangladesh Center for Global Environmental and Occupational Health- Bangladesh 10/06/2022 INTERVENTIONAL unchanged 1,420.85 0 Depression, Aging, Stress and Heart Health Study 10/07/2022 INTERVENTIONAL unchanged 1,419.85 0 Community-based, Controlled, Open-label, Cluster-randomized Trial for the Reduction of Chronic Malnutrition in Children Under Two Years of Age, With Three Intervention Arms Grouped by Clusters, in Two Provinces in Southern Angola, Huíla and Cunene. 10/07/2022 INTERVENTIONAL unchanged 1,419.85 0 Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis 10/07/2022 INTERVENTIONAL unchanged 1,419.85 0 The Rechallenge of ADCs in MBC Patients 10/07/2022 OBSERVATIONAL unchanged 1,419.85 0 Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer 10/10/2022 INTERVENTIONAL unchanged 1,416.85 0 Comparison of the Accuracy of US, MRI and PET/CT in the Assessment of LNs in Cervical Cancer. 10/10/2022 OBSERVATIONAL unchanged 1,416.85 0 Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype 10/10/2022 OBSERVATIONAL unchanged 1,416.85 0 Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study) 10/12/2022 OBSERVATIONAL unchanged 1,414.85 0 Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study 10/12/2022 INTERVENTIONAL unchanged 1,414.85 0 STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision 10/13/2022 INTERVENTIONAL unchanged 1,413.85 0 Healthy Lifestyle Before and During Pregnancy to Prevent Childhood Obesity - the PRE-STORK-trial 10/13/2022 INTERVENTIONAL unchanged 1,413.85 0
Source U.S. National Library of Medicine, ClinicalTrials.gov API v2 · official record · retrieved 08/26/2026 · upstream last modified 08/26/2026
Licence United States government work; public domain unless the source record says otherwise. Source: U.S. National Library of Medicine
Required notice Study records are informational and do not provide diagnosis, treatment advice, or an assessment of individual risk. What we add We compute Vuga Group, Change Status, Recency Days, Public Significance Score using the documented compute method. · methodology